Role of appropriate surgery in survival of patients with epithelial ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 1, 2011, Pages 253-257

  Gaemmaghami, F ^a   Yousefi, Z ^a   Gilani, M ^a   Mosavi, A ^a   Shariat, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Appropriate surgery; Cytoreduction; Epithelial ovarian cancer; Surgical staging

Indexed keywords

EID: 79958760664     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ayhan A, Gultekin M, Celik NY, et al. (2007). Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol, 196, 81. e1-6.
2. Ayhan A, Gultekin M, Taskiran C, et al. (2006). The role of secondary cytoreduction in the treatment of ovarian cancer: hacettepe university experience. Am J of Obst Gynecol, 194, 49-56.
3. Bell J, Brady MF, Young RC, et al. (2006). Gynecologic oncology group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol, 102, 432-.
4. Bookman MA. (2003). Developmental chemotherapy andmanagement of recurrent ovarian cancer. J Clin Oncol, 21, 149-67.
5. Bookman MA, Brady MF, Mc Guiure WP, et al. (2009). Evaluation a new platinum-based treatment regimens' in advanced -stage ovarian-cancer. A phase III trial of the gynecologic cancer Intergroup. J Clin Oncol, 27, 1419-25.
6. Bristow RE, Eisenhauer EL, Santillan A, et al. (2007). Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neo adjuvant chemotherapy and interval cytoredution. Gynecol Oncol, 105, 801-12.
7. Bristow RE, Tomacruz RS, Hemming D, et al. (2000). Optimal cytoreductive surgery in an independent prognostic indicator in stage II epithelial ovarian cancer with hepatic metastases. Gynecol Oncol, 78, 171-5.
8. Bristow RE, Zahurak ML, del Carmen MG, et al. (2004). Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol ncol, 93, 353-36.
9. Cheng X, Jiang R, Li ZT, et al. (2009). The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Eur J Surg Oncol, 35, 1105-8.
10. Colombo N, Guthrie D, Chiari S, et al. (2003). International collaborative ovarian neoplasm (ICON) collaborators. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst, 95, 125-32.
11. Díaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, et al. (2005). Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol, 99, 352-7.
12. Dizon DS, Dupont J, Anderson S, et al. (2003). Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single agent carboplatin originally treated with carboplatin and paclitaxel-the memorial sloan-kettering cancer center experience. Gynecol Oncol, 1, 284-90.
13. Edward J, Tanner, Marinna L, et al. (2008). Surgical care of young women diagnosed with ovarian cancer: a population-based prospective study. Gyencol Oncol, 111, 221-5.
14. Fagotti A, Gallotta V, Romano F, et al. (2010). Role of cytoreductive surgery in recurrent ovarian cancer. Therapy, 7, 87-95.
15. Ghaemmaghami F, Hassanzadeh M, Modarroes Gillani M, et al. (2009). Centralization of ovarian cancer surgery, do patients benefit. Iranian J Gynecol Oncol, 2, 23-33.
16. Gultekin M, Dursun P, Doǧan NU, et al. (2009). Debulking surgery for incompletely operated advanced epithelial ovarian carcinoma. J Surg Oncol, 100, 258-60.
17. Harrison ML, Jameson C, Gore ME. (2008). Mucinous ovarian cancer. Int J Gynecol Cancer, 18, 209-14.
18. Horng HC, Yuan CC, Lai CR, et al. (2007). Presumed Stage IA primary epithelial ovarian carcinoma: the role of complete staging surgery. Eur J Gynaecol Oncol, 28, 43-4.
19. Ivy JJ, Geller M, Pierson SM, et al. (2009). Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience. Gynecol Oncol, 114, 420-3.
20. Jemal A, Siegel R, Ward E, et al. (2009). Cancer statistics, 2009. Cancer J Clin, 59, 225-49.
21. Leblanc E, Querleu D, Narducci F, et al. (2000). Surgical staging of early invasive epithelial ovarian tumors. Semin Surg Oncol, 19, 36-1.
22. Le T, Adolph A, Krepart GV, et al. (2002). The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol, 85, 351-5.
23. McGuire V, Jesser CA, Whittemore AS. (2002). Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol, 4, 399-403.
24. Morrison J, Swanton A, Collins S, et al. (2007). Chemotherapy vs. surgery for initial treatment in advanced ovarian epithelial cancer Cochrane database of systematic vs. online 2007;(4):CD0053430cited 6 times.
25. Munkarah AR, Coleman RL. (2004). Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol, 95, 73-80.
26. Munnell EW (1965). Is conservative therapy ever Justified in stage (Ia) cancer of the ovary. Obstet Gynecol, 103, 641-50.
27. Ozols RF, Markman M, Thigpen JT. (2002). Icon 3 and chemotherapy for ovarian cancer. Lancet, 360, 2086-7.
28. Rose PG, Nerenstone S, Brady MF, et al. (2004). Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engle J Med, 51, 2489-97.
29. Salani R, Axlell A. Gerardi M, et al. (2005). Limited utility of conventional criteria for predicting un resectable disease in patients with advanced stage epithelial ovarian cancer Gyencol Oncol, 109, 364-9.
30. Scholz HS, Tasdemir H, Hunlich T, et al. (2007). Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol, 106, 591-5.
31. Stwart AC. (2007). Long-term Follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (Icon I). J Clin Oncol, 25, 4952-60.
32. Trimbos JB, Schueler MD, Dervan MD, et al. (2006). Watch and wait after carful surgical treatment and staging in well differentiated early ovarian cancer. Cancer Cytopathology, 67, 597-602.
33. Vernooij F, Witteveen PO, Verweij E, et al. (2009). The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients. Gynecol Oncol, 115, 343-8.
34. Winter-Roach BA, Kitchener HC, Dikinson HO.(2009). Adjuvant post-surgery chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev, CD 004906.
35. Young RC.(2003). Early -stage ovarian cancer. To treat or not treat. J Natl Cancer, 95, 94-5.
36. Young RC, Decker DG, Wharton JT, et al. (1983). Staging laparatomy in early ovarian cancer. JAMA, 250, 3072-6.
37. Young RC, Walton LA, Ellenberg SS, et al. (1990). Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med, 322, 1021-7.
38. Zang RY, Li ZT, Tang J, et al. (2004). Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefit? Cancer, 100, 1125-61.